Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 39Unknown 16Active not recruiting 12Terminated 10Recruiting 9Withdrawn 6Not yet recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3Other 1

Conditions

Breast Neoplasms 3Sexual Dysfunctions, Psychological 1HER2-positive Breast Cancer 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Trastuzumab 16pertuzumab 14Capecitabine 14Docetaxel 12pyrotinib 11Cyclophosphamide 11Standard of Care 10Paclitaxel 10Letrozole 10trastuzumab deruxtecan 9Radiotherapy 9Carboplatin 9Fulvestrant 8Drug Therapy 8sacituzumab govitecan 7dalpiciclib 7exemestane 6eribulin 6Tamoxifen 6Epirubicin 6Anastrozole 6pembrolizumab 5palbociclib 5abemaciclib 5Surveys and Questionnaires 5Neoadjuvant Therapy 5Aromatase Inhibitors 5camrelizumab 4Sentinel Lymph Node Biopsy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Breast Neoplasms × Goserelin × Clear all
NCT07287098 2026-05-22

preEMBER

Eli Lilly and Company

Phase 2 Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT05131893 2021-11-23

Neoadjuvant Treatment of Breast Cancer

National Institute of Oncology, Hungary

Not yet recruiting
300 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡